novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Ruxolitinib combined with mesenchymal stem cell
control group: Routine treatment
Sponsors
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years and <= 75 years; 2. Patients clinically diagnosed as novel coronavirus infection; or with positive serum antibodies (IgM or IgG); or with novel coronavirus infection confirmed by PCR; 3. Severe/critical patients.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant tumors requiring treatment; 2. Severe cardiovascular and metabolic diseases beyond the control of combination with other drugs 3. Patients with clinical symptoms of brain dysfunction or serious mental illness who cannot understand or follow the study protocol; 4. Endotracheal intubation with invasive ventilation; 5. Patients who cannot guarantee completion of necessary treatment plan and follow-up observation; 6. Women of child-bearing age who are positive in pregnancy test or do not stop breastfeeding in lactation period; 7. Patients with other infections at the time of enrollment; 8. Other circumstances that prevent the protocol from proceeding safely.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety; | — |
Countries
China
Contacts
Public ContactJianfeng Zhou
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed